Hybridoma Technology: Monoclonal Antibody Production Explained

Added:

Recombinant Antibody Technology and In Vitro Selection Platforms

While hybridoma technology revolutionized monoclonal antibody (mAb) production, it has significant limitations that modern recombinant technologies aim to overcome. Hybridoma relies on animal immunization, raising ethical concerns and restricting antibody generation against highly toxic or conserved antigens. Furthermore, murine-derived hybridoma antibodies can trigger adverse immunogenic responses in human patients, requiring complex humanization processes. In contrast, recombinant methods like phage display, yeast display, and single B-cell cloning allow for the fully in vitro selection of antibodies. These alternative platforms bypass the constraints of animal immune systems, significantly accelerate production timelines, and enable the direct generation of fully human antibodies. By eliminating animal use and offering greater control over antibody affinity and specificity, recombinant technology serves as a major, modern alternative to traditional hybridoma-based production.

Basic structure and function of antibodies (immunoglobulins) and how they specifically bind to antigens.
The role of B-lymphocytes (B cells) in the adaptive immune response, specifically their ability to produce unique antibodies.
The difference between polyclonal and monoclonal antibodies in terms of their specificity, production, and biological origin.
Fundamental concepts of cell biology, particularly cell culture techniques, cell fusion (somatic hybridization), and the nature of immortalized cancer cells (myelomas).
The mechanisms and significance of antibody humanization (chimeric, humanized, and fully human antibodies) to prevent adverse immune responses in patients.
Clinical and therapeutic applications of monoclonal antibodies (mAbs) in treating diseases like cancer, autoimmune disorders, and viral infections.
Diagnostic and laboratory applications of monoclonal antibodies, including ELISA, immunohistochemistry, and flow cytometry.
Alternative, modern methods of antibody production, such as phage display technology, single-cell B-cell cloning, and recombinant DNA technology.
41.8K views726likes7:41@CreativeDiagnosticsOriginal Release: 2020-01-21

Hybridoma technology, developed by Milstein and Kohler in 1975 and awarded the Nobel Prize in 1984, enables the production of monoclonal antibodies through a multi-step process: immunizing mice with an antigen to stimulate B lymphocytes, fusing these activated B cells with immortal myeloma cells to create hybridomas, selecting viable hybridomas using HAT medium (which eliminates unfused cells by blocking nucleotide synthesis pathways), isolating individual hybridoma clones through limiting dilution, screening for desired antibody specificity using techniques like ELISA, and finally characterizing and storing the monoclonal antibodies for therapeutic and diagnostic applications.